AstraZeneca's Symbicort Inhaler Triggers Patent Suit

Law360, New York (January 3, 2012, 4:09 PM EST) -- Texas-based Accuhale LLC hit AstraZeneca PLC with a patent infringement suit Thursday, claiming the pharmaceutical giant violated federal law with its Symbicort pressurized metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease.

According to the suit, AstraZeneca and its French, Swedish and U.S. units infringed U.S. Patent Number 5,718,355 when they manufactured and sold the inhaler. The patent is entitled "Indicator device responsive to axial force for use with inhaler."

"Upon information and belief, and without authority, consent, right or license, and in...
To view the full article, register now.